Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Fresenius    FRE   DE0005785604

FRESENIUS (FRE)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Fresenius, Fresenius Medical Care Shares Fall on Revised Outlook

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/07/2018 | 10:40am CET

By Patrick Costello

Shares of Fresenius fell sharply Friday morning after the German healthcare provider adjusted its midterm guidance and warned it would miss its 2020 group targets late Thursday.

Fresenius said it expects to see mid-single-digit organic sales growth for 2019 compared with earlier forecasts that had group sales increasing at a compounded annual growth rate, or CAGR, of 7.1% to 10.3% through 2020.

Net income for 2019 would remain "broadly stable" compared with 2018, Fresenius said. Its previous forecasts saw group net income increasing at a CAGR of 8.3% to 12.6% through 2020.

At GMT 0910, Fresenius SE was 10% lower at EUR42.56. The company is down nearly 34% in the year to date.

Shares of Fresenius Medical Care, a provider of dialysis products and services that is partially owned by Fresenius SE, also fell Friday after it said 2019 sales growth and net income would be in line with levels recorded in 2018.

Fresenius Medical Care's shares were down 6.9% at EUR63.38.

Bryan Garnier said both companies' shares will remain under pressure until they release more detailed guidance along with full-year earnings Feb. 20.

Fresenius's decision to revise its 2020 targets is "no surprise whatsoever," Berenberg said, adding that the existing 2020 targets had already been rendered "completely meaningless" due to events like the divestiture of Sound and the pending acquisition of NxStage.

The revised forecasts should be taken positively once investors work out the implications, the bank said.

Write to Patrick Costello at Patrick.Costello@dowjones.com.

Stocks mentioned in the article
ChangeLast1st jan.
FRESENIUS -2.38% 41 Delayed Quote.-36.99%
FRESENIUS MEDICAL CARE -0.50% 59.2 Delayed Quote.-32.56%
FRESENIUS SE & CO KGAA --End-of-day quote.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on FRESENIUS
12/14FRESENIUS : wins award for compensatory time account calculator
PU
12/12FRESENIUS SE & CO. KGAA : Notification and public disclosure of transactions by ..
EQ
12/11FRESENIUS : UKEF and VAMED agree framework to boost UK healthcare exports
AQ
12/11BASF cuts outlook, now sees profits falling 15-20 percent in 2018
RE
12/10EUROPE MARKETS: European Stocks End Sharply Lower As Data Add To Worries Abou..
DJ
12/10FRESENIUS : UKEF and VAMED agree framework to boost UK healthcare exports
AQ
12/10FRESENIUS SE & CO. KGAA : Notification and public disclosure of transactions by ..
EQ
12/07Akorn CEO Retires Following Court Ruling
DJ
12/07FRESENIUS : Delaware Supreme Court upholds Fresenius' termination of merger agre..
PU
12/07FRESENIUS : Delaware Supreme Court Upholds Fresenius' Termination Of Merger Agre..
DJ
More news
Financials (€)
Sales 2018 33 465 M
EBIT 2018 4 940 M
Net income 2018 1 986 M
Debt 2018 15 866 M
Yield 2018 1,92%
P/E ratio 2018 11,56
P/E ratio 2019 11,51
EV / Sales 2018 1,16x
EV / Sales 2019 1,07x
Capitalization 22 805 M
Chart FRESENIUS
Duration : Period :
Fresenius Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FRESENIUS
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 62,9 €
Spread / Average Target 53%
EPS Revisions
Managers
NameTitle
Stephan Sturm President & Chief Executive Officer
Gerd Krick Chairman-Supervisory Board
Rachel Clare Empey Chief Financial Officer
Niko Stumpfögger Deputy Chairman-Supervisory Board
Klaus-Peter Müller Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
FRESENIUS-36.99%26 421
BANGKOK DUSIT MEDICAL SERVICES PCL--.--%12 414
IHH HEALTHCARE BHD--.--%11 321
AIER EYE HOSPITAL GROUP CO LTD--.--%10 176
RAMSAY HEALTH CARE LIMITED-21.82%7 897
PREMIER INC26.31%5 056